American Gene Technologies Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$310K
- Investors
-
14
American Gene Technologies General Information
Description
Developer of gene and cell therapy designed to cure infectious diseases, cancers, and inherited disorders. The company's therapy has three patents to make the cell product functionally cure HIV individuals, and ten patents for its immuno-oncology approach to stimulate gamma-delta T cells to eliminate a variety of human solid tumors has developed a synthetic gene, enabling physicians to get effective drugs to treat Phenylketonuria (PKU) patients.
Contact Information
Website
www.americangene.comCorporate Office
- 9713 Key West Avenue
- 5th Floor
- Rockville, MD 20850
- United States
Corporate Office
- 9713 Key West Avenue
- 5th Floor
- Rockville, MD 20850
- United States
American Gene Technologies Timeline
American Gene Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 22-Dec-2025 | $310K | Completed | Clinical Trials - General | ||
| 12. Later Stage VC | 21-Jan-2025 | Completed | Clinical Trials - General | |||
| 11. Later Stage VC (Series F) | 30-Apr-2022 | Completed | Clinical Trials - General | |||
| 10. Later Stage VC (Series E2) | 14-Mar-2021 | Completed | Clinical Trials - General | |||
| 9. Angel (individual) | 01-Sep-2020 | Completed | Clinical Trials - General | |||
| 8. Debt - PPP | 13-Apr-2020 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series E1) | 14-Feb-2019 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D1) | 30-Nov-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C1) | 26-Apr-2016 | $4.1M | $6.9M | Completed | Generating Revenue | |
| 4. Seed Round | 30-Apr-2015 | $1.8M | $2.8M | Completed | Generating Revenue |
American Gene Technologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E1 | ||||||||
| Series D1 | ||||||||
| Series C1 | ||||||||
| Series B1 | 4,166,666 | $0.000100 | $0.04 | $0.48 | $0.48 | 1x | $0.48 | 7.86% |
| Series A1 | 2,170,610 | $0.000100 | $0.04 | $0.46 | $0.46 | 1x | $0.46 | 4.1% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
American Gene Technologies Comparisons
Industry
Financing
Details
American Gene Technologies Competitors (94)
One of American Gene Technologies’s 94 competitors is Senti Biosciences Holdings, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA | ||||
| Phaxiam | Formerly VC-backed | Lyon, France | ||||
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
American Gene Technologies Patents
American Gene Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4780472-A2 | Hiv vaccination and immunotherapy | Pending | 22-Sep-2023 | ||
| WO-2025064901-A2 | Hiv vaccination and immunotherapy | Inactive | 22-Sep-2023 | ||
| WO-2025064901-A3 | Hiv vaccination and immunotherapy | Inactive | 22-Sep-2023 | ||
| WO-2025050047-A1 | Combination immunotherapy and antiviral treatment | Inactive | 01-Sep-2023 | ||
| AU-2022211039-A1 | Engineered nk cells and methods of treating cancer | Pending | 21-Jan-2021 | A61K40/15 |
American Gene Technologies Signals
American Gene Technologies Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Carat Venture Partners | Venture Capital | Minority | ||
| MCMA Ventures | Venture Capital | Minority | ||
| Opus8 | PE/Buyout | Minority | ||
| Ossian Capital | Venture Capital | Minority | ||
| Ride Wave Ventures | Venture Capital | Minority |
American Gene Technologies FAQs
-
When was American Gene Technologies founded?
American Gene Technologies was founded in 2007.
-
Where is American Gene Technologies headquartered?
American Gene Technologies is headquartered in Rockville, MD.
-
What is the size of American Gene Technologies?
American Gene Technologies has 25 total employees.
-
What industry is American Gene Technologies in?
American Gene Technologies’s primary industry is Drug Discovery.
-
Is American Gene Technologies a private or public company?
American Gene Technologies is a Private company.
-
What is American Gene Technologies’s current revenue?
The current revenue for American Gene Technologies is .
-
How much funding has American Gene Technologies raised over time?
American Gene Technologies has raised $81.3M.
-
Who are American Gene Technologies’s investors?
Carat Venture Partners, MCMA Ventures, Opus8, Ossian Capital, and Ride Wave Ventures are 5 of 14 investors who have invested in American Gene Technologies.
-
Who are American Gene Technologies’s competitors?
Senti Biosciences Holdings, Phaxiam, Orchard Therapeutics, Immusoft, and Inovio Pharmaceuticals are some of the 94 competitors of American Gene Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process